HVDP for Health Canada [Regulatives / Guidelines]

posted by balakotu – India, 2017-03-21 13:16 (2887 d 14:37 ago) – Posting: # 17171
Views: 2,607

Dear All,

Please clarify,

As per recent approach for highly variable drug products, health Canada accepts studies in full replicate or partial replicate design with widening of confidence intervals for AUC.

For such studies that will be conducted in full replicate or partial replicate studies for health Canada submissions, how to evaluate the subjects completing only two treatment periods; one with test product and other with reference product i.e (TR or RT).

Whether these subjects should be included or excluded for Bioequivalence assessment.

Regards
Kotu

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
78 visitors (0 registered, 78 guests [including 12 identified bots]).
Forum time: 03:54 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5